Bicycle Therapeutics PLC (BCYC)
22.06
+0.21
(+0.96%)
USD |
NASDAQ |
May 15, 14:29
Bicycle Therapeutics Free Cash Flow: -85.93M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -85.93M |
| December 31, 2023 | -63.56M |
| September 30, 2023 | -47.98M |
| June 30, 2023 | -55.30M |
| March 31, 2023 | -122.45M |
| December 31, 2022 | -105.10M |
| September 30, 2022 | -84.84M |
| June 30, 2022 | -54.44M |
| March 31, 2022 | -33.65M |
| December 31, 2021 | -16.82M |
| September 30, 2021 | -22.42M |
| Date | Value |
|---|---|
| June 30, 2021 | -54.05M |
| March 31, 2021 | -54.16M |
| December 31, 2020 | -18.99M |
| September 30, 2020 | -7.198M |
| June 30, 2020 | -8.286M |
| March 31, 2020 | -3.707M |
| December 31, 2019 | -30.17M |
| September 30, 2019 | -34.12M |
| June 30, 2019 | -27.74M |
| March 31, 2019 | -25.35M |
| December 31, 2018 | -27.26M |
Free Cash Flow Range, Past 5 Years
-122.45M
Minimum
Mar 2023
-3.707M
Maximum
Mar 2020
-46.55M
Average
-41.05M
Median
Free Cash Flow Benchmarks
| Biodexa Pharmaceuticals Plc | -8.842M |
| NuCana PLC | -33.49M |
| TC BioPharm (Holdings) PLC | -13.42M |
| Adaptimmune Therapeutics PLC | -145.76M |
| Verona Pharma PLC | -58.07M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -70.87M |
| Cash from Investing (Quarterly) | -0.012M |
| Cash from Financing (Quarterly) | 1.871M |
| Free Cash Flow Per Share (Quarterly) | -1.665 |
| Free Cash Flow to Equity (Quarterly) | -70.98M |
| Free Cash Flow to Firm (Quarterly) | -70.88M |
| Free Cash Flow Yield | -10.06% |